Skip to main content Skip to main navigation menu Skip to site footer

Does NAFLD Fibrosis Score predict mortality risk among MAFLD patients?: a systematic review and meta-analysis



Abstract

Background: Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD) is a prevalent liver disease affecting 1 million people and projected to be the leading cause of liver transplantation in 2030 due to its progression of liver fibrosis. Several non-invasive scoring systems have been established to predict advanced fibrosis among MAFLD patients, namely NAFLD Fibrosis Score (NFS). Whether its performance remains useful in determining mortality risk in the MAFLD population is less clear. This study was aimed to assess the usefulness of NFS to predict mortality risk among MAFLD patients.

Method: A systematic search was conducted on Pubmed, ProQuest, and ScienceDirect from inception to February 28, 2021. All studies that met the inclusion criteria investigating MAFLD patients diagnosed with biopsy or non-biopsy were included. Bias risk was assessed using The Newcastle-Ottawa Scale. The outcome was mortality risk. We used a random-effects model, and data were pooled to determine the risk ratio (RR) and its 95% CI. Meta-analysis was conducted using Review Manager 5.3.

Result: 9 cohort studies comprising 21,041 MAFLD patients were included. The risk of bias was found to be low. Pooled analysis showed that high NFS (>0.676) was significantly associated with increased mortality (RR=3.14; 95%CI=2.35-4.19; p<0.0; I2=89%). The finding was more prominent in the biopsy-proven MAFLD subgroup (RR=3.75; 95%CI=2.20-6.38; p<0.00).

Conclusion: High NFS is associated with an increased risk of death in MAFLD patients. 

Keywords: NFS MAFLD NAFLD mortality prognostic

References

  1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-9. doi: 10.1016/j.jhep.2020.03.039.
  2. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53(6):1874-82. doi: 10.1002/hep.24268.
  3. Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, et al. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One. 2015;10(6):e0128774. doi: 10.1371/journal.pone.0128774
  4. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-54. doi: 10.1002/hep.27368.
  5. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043.
  6. Leung JC, Loong TC, Wei JL, Wong GL, Chan AW, Choi PC, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65(1):54-64. doi: 10.1002/hep.28697
  7. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. doi: 10.1002/hep.29367.
  8. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple non-invasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(4):782-9.e4. doi: 10.1053/j.gastro.2013.06.057.
  9. Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19(8):1219-29. doi: 10.3748/wjg.v19.i8.1219.
  10. Xun YH, Guo JC, Lou GQ, Jiang YM, Zhuang ZJ, Zhu MF, et al. Nonalcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD. Clin Exp Pharmacol Physiol. 2014;41(9):643-9. doi: 10.1111/1440-1681.12260.
  11. Unalp-Arida A, Ruhl CE. Non-invasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology. 2016;63(4):1170-83. doi: 10.1002/hep.28390.
  12. Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, et al. Prevalence of nonalcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12(3):e0173499. doi: 10.1371/journal.pone.0173499
  13. Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A. Non-invasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PLoS One. 2018;13(8):e0202393. doi: 10.1371/journal.pone.0202393.
  14. Golabi P, Stepanova M, Pham HT, Cable R, Rafiq N, Bush H, et al. Nonalcoholic steatofibrosis (NASF) can independently predict mortality in patients with nonalcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol. 2018;5(1):e000198. doi: 10.1136/bmjgast-2018-000198.
  15. Hagström H, Nasr P, Ekstedt M, Stål P, Hultcrantz R, Kechagias S. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019;17(6):1148-56.e4. doi: 10.1016/j.cgh.2018.11.030.
  16. Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611-25.e12. doi: 10.1053/j.gastro.2020.01.043.
  17. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486-501. doi: 10.1002/hep.29302.
  18. Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in nonalcoholic fatty liver disease. J Hepatol. 2016;65(3):570-8. doi: 10.1016/j.jhep.2016.04.023.
  19. Han MAT, Vipani A, Noureddin N, Ramirez K, Gornbein J, Saouaf R, et al. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. Liver Int. 2020;40(9):2242-51. doi: 10.1111/liv.14593.
  20. Petta S, Sebastiani G, Viganò M, Ampuero J, Wai-Sun Wong V, Boursier J, et al. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clin Gastroenterol Hepatol. 2021;19(4):806-15.e5. 10.1016/j.cgh.2020.06.045
  21. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54. doi: 10.1002/hep.21496.

How to Cite

Rahadini, A. A. D., & Rahadina, A. (2021). Does NAFLD Fibrosis Score predict mortality risk among MAFLD patients?: a systematic review and meta-analysis. Bali Medical Journal, 10(2), 595–599. https://doi.org/10.15562/bmj.v10i2.2359
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
16

Share

Search Panel

Adinda Ayu Dyah Rahadini
Google Scholar
Pubmed
BMJ Journal

Adinda Rahadina
Google Scholar
Pubmed
BMJ Journal